Halozyme Therapeutics, Inc. vs. Tarsus Pharmaceuticals, Inc. Common Stock
HALO
Halozyme Therapeutics, Inc.
$113.90 -1.15%
VS TARSTarsus Pharmaceuticals, Inc. Common Stock
$74.29 -3.62%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| HALO | TARS | |
|---|---|---|
| Market Cap | $12.93 billion | $3.61 billion |
| Revenue (TTM) | $1.66 billion | $606.33 million |
| Net Income (TTM) | $413.60 million | $-46,476,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | TARS | |
|---|---|---|
| P/E Ratio | 33.21 | — |
| Price / Book | 90.06 | 10.40 |
| Price / Sales | 7.77 | 5.95 |
TARS leads on 2 of 2 valuation factors.
Profitability
| HALO | TARS | |
|---|---|---|
| Net Margin | 24.86% | -7.67% |
| Return on Equity | 288.13% | -13.40% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| HALO | TARS | |
|---|---|---|
| Short Interest | 9.79% | 0.31% |
TARS leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, TARS overview, TARS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.